Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264, USA.
Cancer Res. 2011 Oct 15;71(20):6300-9. doi: 10.1158/0008-5472.CAN-11-1374.
To enable antibodies to function as cytotoxic anticancer agents, they are modified either via attachment to protein toxins or highly potent, low-molecular-weight drugs. Such molecules, termed immunotoxins and antibody-drug conjugates, respectively, represent a second revolution in antibody-mediated cancer therapy. Thus, highly toxic compounds are delivered to the interior of cancer cells based on antibody specificity for cell-surface target antigens.
为了使抗体能够发挥细胞毒性抗癌作用，可以通过与蛋白毒素或高活性、低分子量药物结合进行修饰。这些分子分别被称为免疫毒素和抗体药物偶联物，代表了抗体介导的癌症治疗的第二次革命。因此，根据抗体对细胞表面靶抗原的特异性，将高毒性化合物递送到癌细胞内部。
